secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMGC Holdings Inc. (ELAB)
CIK:        0001840563
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001213900-26-035098
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMGC subsidiary Northstrive and MOA amend license milestones for BLS-M22, add amendment fee
--------------------------------------------------------------------------------

- Third Amendment updates development milestones for human health field, including pre-clinical, IND, Phase 1-3, FDA marketing approval.
- For BLS-M22, Phase 1 trial may be excused; milestone payment deferred to Phase 2 start.
- PMGC to pay MOA a one-time amendment fee within 30 days of effective date (amount redacted).
- Amendment effective as of March 24, 2026; signed by CEO Graydon Bensler and MOA COO Tiger Yoon.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840563/000121390026035098/0001213900-26-035098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840563/000121390026035098/ea0283722-8k_pmgc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-035098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer